Great flash talks from Anton Patrikeev (HPV evolution in head and neck cancer) and Florian Gabel (resistance evolution in prostate cancer) both from our @cec-icr.bsky.social @icr.ac.uk #CrickCancerConf

In this perspective, we examined the present and future interface of AI & translational cancer research for @cp-cancercell.bsky.social - led by the stellar Dr. Josephine Yates! @danafarber.bsky.social @broadinstitute.org www.sciencedirect.com/science/arti...

Here's our latest - jointly with @rhaq1.bsky.social lab & co-lead by Drs. Schiantarelli, Benamar, Park et al - studying why some tumors stop responding to immunotherapy. This continues to be a tough puzzle to solve, but important for science & patients alike...

#SaveThePCC

Some of you may have read about the situation regarding our new landlord wishing to add a new redevelopment break clause, with only 6 months notice to our lease.

For now, we're simply asking you all to share & sign the petition below;

you.38degrees.org.uk/p/princechar...

PARP inhibitor, olaparib, has transformed treatment for men whose #prostatecancer has DNA repair defects, but most cancers eventually become resistant.

@seedgeorge.bsky.social at @icrlondon.bsky.social has uncovered genomic changes that predict how long men will respond.🧵

doi.org/10.1016/j.cc...

Delighted that a major project of my post-doctoral fellowship in the de Bono lab has been published. A really interesting story, featuring the likes of @icrlordlab.bsky.social @boragurel.bsky.social among many others at @icrlondon.bsky.social and elsewhere.

This weeks coffee club paper focuses on genomic changes linked to PARP inhibitor resistance ☕

The work was led by @prostatecanceruk.bsky.social's Travel Prize Fellow @seedgeorge.bsky.social from @icrlondon.bsky.social

Congratulations to George and team 🥳

t.co/rC22HnAKIs

#prostatecancer #research